208 related articles for article (PubMed ID: 21798616)
1. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
[TBL] [Abstract][Full Text] [Related]
2. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
4. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
5. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
6. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
Lukasova M; Malaval C; Gille A; Kero J; Offermanns S
J Clin Invest; 2011 Mar; 121(3):1163-73. PubMed ID: 21317532
[TBL] [Abstract][Full Text] [Related]
7. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
Li X; Millar JS; Brownell N; Briand F; Rader DJ
Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
[TBL] [Abstract][Full Text] [Related]
8. GPR109A and vascular inflammation.
Chai JT; Digby JE; Choudhury RP
Curr Atheroscler Rep; 2013 May; 15(5):325. PubMed ID: 23526298
[TBL] [Abstract][Full Text] [Related]
9. The Role of GPR109a Signaling in Niacin Induced Effects on Fed and Fasted Hepatic Metabolism.
Geisler CE; Miller KE; Ghimire S; Renquist BJ
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924461
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.
Hanson J; Gille A; Zwykiel S; Lukasova M; Clausen BE; Ahmed K; Tunaru S; Wirth A; Offermanns S
J Clin Invest; 2010 Aug; 120(8):2910-9. PubMed ID: 20664170
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cells release prostaglandin D2 in response to nicotinic acid.
Maciejewski-Lenoir D; Richman JG; Hakak Y; Gaidarov I; Behan DP; Connolly DT
J Invest Dermatol; 2006 Dec; 126(12):2637-46. PubMed ID: 17008871
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in niacin and lipid metabolism.
Kamanna VS; Ganji SH; Kashyap ML
Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
[TBL] [Abstract][Full Text] [Related]
13. Seeing red: flushing out instigators of niacin-associated skin toxicity.
Dunbar RL; Gelfand JM
J Clin Invest; 2010 Aug; 120(8):2651-5. PubMed ID: 20664168
[TBL] [Abstract][Full Text] [Related]
14. Future of GPR109A agonists in the treatment of dyslipidaemia.
Wanders D; Judd RL
Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
[TBL] [Abstract][Full Text] [Related]
15. Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin.
Hanson J; Gille A; Offermanns S
Pharmacol Ther; 2012 Oct; 136(1):1-7. PubMed ID: 22743741
[TBL] [Abstract][Full Text] [Related]
16. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.
Elangovan S; Pathania R; Ramachandran S; Ananth S; Padia RN; Lan L; Singh N; Martin PM; Hawthorn L; Prasad PD; Ganapathy V; Thangaraju M
Cancer Res; 2014 Feb; 74(4):1166-78. PubMed ID: 24371223
[TBL] [Abstract][Full Text] [Related]
17. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects.
Jiang Y; Jin M; Chen J; Yan J; Liu P; Yao M; Cai W; Pi R
Eur J Pharmacol; 2020 Feb; 868():172871. PubMed ID: 31846627
[TBL] [Abstract][Full Text] [Related]
19. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.
Walters RW; Shukla AK; Kovacs JJ; Violin JD; DeWire SM; Lam CM; Chen JR; Muehlbauer MJ; Whalen EJ; Lefkowitz RJ
J Clin Invest; 2009 May; 119(5):1312-21. PubMed ID: 19349687
[TBL] [Abstract][Full Text] [Related]
20. Niacin stimulates adiponectin secretion through the GPR109A receptor.
Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
